| P50 | author | Yoshifumi Shimada | Q91014087 |
| | Toshifumi Wakai | Q91553465 |
| | Jun Sakata | Q91603713 |
| P2093 | author name string | Masayuki Nagahashi | |
| | Pankaj Prasoon | |
| P2860 | cites work | MUC1 peptide vaccination in patients with advanced pancreas or biliary tract cancer | Q81062411 |
| | Exome sequencing of liver fluke-associated cholangiocarcinoma | Q84073724 |
| | Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma | Q84847484 |
| | Phase 1b investigation of the MEK inhibitor binimetinib in patients with advanced or metastatic biliary tract cancer | Q88766400 |
| | Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial | Q90365007 |
| | The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity | Q91013772 |
| | Worldwide trends in mortality from biliary tract malignancies | Q21093310 |
| | Global cancer statistics | Q22241238 |
| | Immunotherapeutic approaches in biliary tract carcinoma: Current status and emerging strategies | Q26776184 |
| | Cholangiocarcinoma | Q27001694 |
| | Identification of targetable FGFR gene fusions in diverse cancers. | Q27852147 |
| | Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. | Q27852601 |
| | TRKing down an old oncogene in a new era of targeted therapy | Q28254287 |
| | A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma | Q28261572 |
| | PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | Q28262647 |
| | Classification, diagnosis, and management of cholangiocarcinoma | Q28275153 |
| | Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation | Q28609161 |
| | Signatures of mutational processes in human cancer | Q29547191 |
| | Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan | Q33390747 |
| | A multi-institution phase II study of gemcitabine/cisplatin/S-1 (GCS) combination chemotherapy for patients with advanced biliary tract cancer (KHBO 1002). | Q33419175 |
| | Overexpression of the HER2/neu Gene: A New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer | Q33557258 |
| | Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas | Q33581027 |
| | Kinase fusions are frequent in Spitz tumours and spitzoid melanomas | Q33854847 |
| | Genomic and genetic characterization of cholangiocarcinoma identifies therapeutic targets for tyrosine kinase inhibitors | Q34104493 |
| | Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma | Q34160782 |
| | K-ras mutation is strongly associated with perineural invasion and represents an independent prognostic factor of intrahepatic cholangiocarcinoma after hepatectomy | Q34340578 |
| | The landscape of kinase fusions in cancer | Q34437602 |
| | Cancer risks in BRCA2 mutation carriers | Q34504452 |
| | Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. | Q34557699 |
| | Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer | Q34618537 |
| | Clinical diagnosis and staging of cholangiocarcinoma | Q34631337 |
| | Pathogenesis, diagnosis, and management of cholangiocarcinoma | Q34656747 |
| | Mutation profiling in cholangiocarcinoma: prognostic and therapeutic implications | Q34764681 |
| | New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing | Q35100996 |
| | Molecular characterization of gallbladder cancer using somatic mutation profiling | Q35597012 |
| | Conferring specificity on the ubiquitous Raf/MEK signalling pathway | Q35634546 |
| | HER2/neu-directed therapy for biliary tract cancer | Q35748129 |
| | The epidemiology of cholangiocarcinoma | Q35802314 |
| | Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer | Q35842729 |
| | Biliary carcinomas: pathology and the role of DNA mismatch repair deficiency. | Q36187672 |
| | Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma | Q36614705 |
| | Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma. | Q37588461 |
| | Therapeutic implication of HER2 in advanced biliary tract cancer | Q37628969 |
| | Cholangiocarcinoma: epidemiology, risk factors, pathogenesis, and diagnosis | Q37832697 |
| | Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities | Q38116645 |
| | Proximal biliary tumors | Q38200214 |
| | Surgery for Recurrent Biliary Tract Cancer: A Single-center Experience With 74 Consecutive Resections | Q38269088 |
| | HER2 expression status in diverse cancers: review of results from 37,992 patients | Q38364900 |
| | New Horizons for Precision Medicine in Biliary Tract Cancers | Q38619219 |
| | Whole-exome and targeted gene sequencing of gallbladder carcinoma identifies recurrent mutations in the ErbB pathway | Q38977752 |
| | Biliary cancer: Utility of next-generation sequencing for clinical management | Q39396785 |
| | Marked radiographic response of a HER-2-overexpressing biliary cancer to trastuzumab | Q42033747 |
| | Deficient expression of O(6)-methylguanine-DNA methyltransferase combined with mismatch-repair proteins hMLH1 and hMSH2 is related to poor prognosis in human biliary tract carcinoma | Q43977676 |
| | Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers | Q45704144 |
| | Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers | Q46488823 |
| | BRAF V600E-specific immunohistochemistry reveals low mutation rates in biliary tract cancer and restriction to intrahepatic cholangiocarcinoma | Q46509671 |
| | Phase II Study of BGJ398 in Patients With FGFR-Altered Advanced Cholangiocarcinoma. | Q47403256 |
| | Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study | Q47556085 |
| | Hypermutation and microsatellite instability in gastrointestinal cancers | Q47655313 |
| | Efficacy and safety of trametinib in Japanese patients with advanced biliary tract cancers refractory to gemcitabine. | Q48333251 |
| | Genomic Characterization of Biliary Tract Cancers Identifies Driver Genes and Predisposing Mutations. | Q48526884 |
| | IDH mutations: new genetic signatures in cholangiocarcinoma and therapeutic implications | Q49185595 |
| | HER kinase inhibition in patients with HER2- and HER3-mutant cancers | Q50115014 |
| | c-erbB-2 and c-Met expression relates to cholangiocarcinogenesis and progression of intrahepatic cholangiocarcinoma. | Q52122642 |
| | Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. | Q52692152 |
| | Dramatic response to trastuzumab and paclitaxel in a patient with human epidermal growth factor receptor 2-positive metastatic cholangiocarcinoma. | Q53149260 |
| | Genomic spectra of biliary tract cancer. | Q53390123 |
| | The TRK-T1 fusion protein induces neoplastic transformation of thyroid epithelium. | Q53403133 |
| | A significant subgroup of resectable gallbladder cancer patients has an HER2 positive status. | Q54222781 |
| | Mutational landscape of intrahepatic cholangiocarcinoma. | Q54300991 |
| | HER3 overexpression is a prognostic indicator of extrahepatic cholangiocarcinoma. | Q54478596 |
| | Mutations in the RAS/RAF/MAP kinase pathway commonly occur in gallbladder adenomas but are uncommon in gallbladder adenocarcinomas. | Q54614090 |
| | Clinical practice guidance for next-generation sequencing in cancer diagnosis and treatment (Edition 1.0) | Q56516340 |
| | Distal cholangiocarcinoma | Q57153427 |
| | Gallbladder cancer | Q57642864 |
| | Carcinoma of the gallbladder | Q73093603 |
| | Infrequent microsatellite instability in biliary tract cancer | Q73552697 |
| | K-ras mutation, p53 overexpression, and microsatellite instability in biliary tract cancers: a population-based study in China | Q78358414 |
| P433 | issue | 4 | |
| P921 | main subject | ??? | Q18556397 |
| P304 | page(s) | 316-323 | |
| P577 | publication date | 2020-04-14 | |
| P1433 | published in | Annals of Gastroenterological Surgery | Q50817800 |
| P1476 | title | Genetic analysis in the clinical management of biliary tract cancer | |
| P478 | volume | 4 | |